Ahmed M Arzika

Dados Biográficos

ID7001992
NOMEAhmed M Arzika
PRENOMESAhmed M
SOBRENOMEArzika
ASSINATURAARZIKA A M
AFILIAÇÕESCentre de Recherche Médicale et Sanitaire
ORCID0000-0001-7022-282X
VERIFICADOSim
TOTAL DE OBRAS7
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2021
ANO MAIS RECENTE DE PUBLICAÇÃO2026
ÍNDICE H0

  • Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger

    Open AccessBrittany Peterson, William Nguyen et al.ARTICLEPLOS Global Public Health2026

    As programs for azithromycin mass drug administration (AZ-MDA) to reduce child mortality have begun in some parts of West Africa, it is imperative to understand their financial costs. We combined a micro-costing framework and observations from an implementation-focused sub-study within the AVENIR trials in 80 communities in the Dosso region of Niger to estimate the national health sector financial costs of a scaled-up programmatic approach for az…

  • Predictors of home- vs . facility-based delivery among women living in rural Niger

    Open AccessBrittany Peterson, Ahmed M Arzika et al.ARTICLEJournal of Global Health2026

    Background: Niger has one of the highest maternal mortality rates, and facility delivery can help prevent these deaths. While distance to health facilities predicts home delivery in other sub-Saharan African settings, few studies have examined this relationship in Niger. Methods: This cross-sectional survey, an ancillary study to the AVENIR trial, included women aged 12-59 years old with a child participating in a sub-trial of AVENIR. Trained wor…

  • Seasonality of underweight among infants 1–11 months old in Niger

    Open AccessBrittany Peterson, Ahmed M Arzika et al.ARTICLEBMJ Global Health2025

    INTRODUCTION: Malnutrition is a risk factor for child mortality, with around 45% of deaths in children under 5 globally linked to malnutrition. Seasonality of malnutrition has important implications for the timing of child health programme activities, but evidence is mixed on the nature of such patterns. Moreover, the bulk of the existing evidence is focused on wasting and stunting in children 6-59 months, despite increasing evidence that younger…

  • Effect of biannual azithromycin on respiratory pathogens among symptomatic children

    Open AccessJie Liu, Stephanie A Brennhofer et al.ARTICLEBMJ Global Health2025

    Introduction Biannual (ie, every 6 months) mass drug administration of azithromycin has reduced childhood mortality in Niger, but its effects on specific respiratory pathogens are not fully elucidated. Methods Across 2 years of the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) study in Niger, we evaluated 1468 nasopharyngeal swabs from children who presented for care with respiratory symptoms. Swabs were tested b…

  • Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger

    Open AccessAhmed M Arzika, Ramatou Maliki et al.ARTICLEPLOS Global Public Health2023

    Recent evidence indicates mass azithromycin distribution reduces under-5 mortality. This intervention is being considered for child survival programs in high mortality sub-Saharan African settings. The delivery approach used in prior studies required a full-time census and distribution team, which is not feasible for most programs. To determine the optimal programmatic approach to delivery, this study aimed to compare treatment coverage, costs, a…

  • Simplified dosing of oral azithromycin for children 1–11 months old in child survival programmes

    Open AccessHuiyu Hu, Ahmed M Arzika et al.ARTICLEBMJ Global Health2022

    BACKGROUND: To facilitate mass distribution of azithromycin, trachoma control programmes use height instead of weight to determine dose for children 6 months to 15 years old. WHO has recommended azithromycin distribution to children 1-11 months old to reduce mortality in high mortality settings under carefully monitored conditions. Weight was used to determine dose in children 1-5 months old in studies of azithromycin distribution for child survi…

  • Age-based targeting of biannual azithromycin distribution for child survival in Niger

    Open AccessKieran S O’Brien, Ahmed M Arzika et al.ARTICLEBMC Public Health2021

    This trial was registered on January 13, 2020 (clinicaltrials.gov: NCT04224987 )